Anti-Influenza A Virus M2 Protein 抗体 [14C2] (ab5416)

ab5416 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab5416 は 31 報の論文で使用されています。

  • Tutykhina I  et al. Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts. PLoS One 13:e0191574 (2018). PubMed: 29377916
  • Opriessnig T  et al. Comparison of the efficacy of a commercial inactivated influenza A/H1N1/pdm09 virus (pH1N1) vaccine and two experimental M2e-based vaccines against pH1N1 challenge in the growing pig model. PLoS One 13:e0191739 (2018). WB . PubMed: 29381710
  • Fletcher K  et al. The WD40 domain of ATG16L1 is required for its non-canonical role in lipidation of LC3 at single membranes. EMBO J 37:N/A (2018). PubMed: 29317426
  • Perot BP  et al. Autophagy diminishes the early interferon-ß response to influenza A virus resulting in differential expression of interferon-stimulated genes. Cell Death Dis 9:539 (2018). PubMed: 29748576
  • Spronken MI  et al. A compensatory mutagenesis study of a conserved hairpin in the M gene segment of influenza A virus shows its role in virus replication. RNA Biol 14:1606-1616 (2017). PubMed: 28662365
  • Zhu P  et al. Host Cellular Protein TRAPPC6A? Interacts with Influenza A Virus M2 Protein and Regulates Viral Propagation by Modulating M2 Trafficking. J Virol 91:N/A (2017). PubMed: 27795429
  • Turnbull ML  et al. Role of the B Allele of Influenza A Virus Segment 8 in Setting Mammalian Host Range and Pathogenicity. J Virol 90:9263-84 (2016). PubMed: 27489273
  • Nogales A  et al. Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines. J Virol 90:6291-302 (2016). WB . PubMed: 27122587
  • Khaperskyy DA  et al. Selective Degradation of Host RNA Polymerase II Transcripts by Influenza A Virus PA-X Host Shutoff Protein. PLoS Pathog 12:e1005427 (2016). WB . PubMed: 26849127
  • Gaunt E  et al. Elevation of CpG frequencies in influenza A genome attenuates pathogenicity but enhances host response to infection. Elife 5:e12735 (2016). PubMed: 26878752
  • Stepanova LA  et al. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin. PLoS One 10:e0119520 (2015). WB, ELISA . PubMed: 25799221
  • Zheng M  et al. An A14U Substitution in the 3' Noncoding Region of the M Segment of Viral RNA Supports Replication of Influenza Virus with an NS1 Deletion by Modulating Alternative Splicing of M Segment mRNAs. J Virol 89:10273-85 (2015). WB . PubMed: 26223635
  • Ohtsuka J  et al. Vero/BC-F: an efficient packaging cell line stably expressing F protein to generate single round-infectious human parainfluenza virus type 2 vector. Gene Ther N/A:N/A (2014). WB . PubMed: 24942630
  • Sawaengsak C  et al. Intranasal chitosan-DNA vaccines that protect across influenza virus subtypes. Int J Pharm 473:113-25 (2014). PubMed: 24998507
  • Wang L  et al. Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines. Nanomedicine N/A:N/A (2013). PubMed: 23988715
  • He J  et al. Dual function of CD81 in influenza virus uncoating and budding. PLoS Pathog 9:e1003701 (2013). PubMed: 24130495
  • Amorim MJ  et al. Nucleozin targets cytoplasmic trafficking of viral ribonucleoprotein-Rab11 complexes in influenza A virus infection. J Virol 87:4694-703 (2013). PubMed: 23408618
  • Sun E  et al. Dissecting the role of COPI complexes in influenza virus infection. J Virol 87:2673-85 (2013). PubMed: 23255804
  • Seo YJ  et al. Sphingosine kinase 1 serves as a pro-viral factor by regulating viral RNA synthesis and nuclear export of viral ribonucleoprotein complex upon influenza virus infection. PLoS One 8:e75005 (2013). WB . PubMed: 24137500
  • Ma X  et al. Enhancing lysosome biogenesis attenuates BNIP3-induced cardiomyocyte death. Autophagy 8: (2012). PubMed: 22302006
  • Wu CY  et al. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. PLoS One 7:e42363 (2012). PubMed: 22879951
  • Amorim MJ  et al. A rab11- and microtubule-dependent mechanism for cytoplasmic transport of influenza a virus viral RNA. J Virol 85:4143-56 (2011). PubMed: 21307188
  • Song JM  et al. Influenza virus-like particles containing m2 induce broadly cross protective immunity. PLoS One 6:e14538 (2011). WB . PubMed: 21267073
  • Wu CY  et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One 5:e9784 (2010). WB . PubMed: 20339535
  • Read EK & Digard P Individual influenza A virus mRNAs show differential dependence on cellular NXF1/TAP for their nuclear export. J Gen Virol 91:1290-301 (2010). WB . PubMed: 20071484
  • Noton SL  et al. Studies of an influenza A virus temperature-sensitive mutant identify a late role for NP in the formation of infectious virions. J Virol 83:562-71 (2009). WB . PubMed: 18987140
  • Brass AL  et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139:1243-54 (2009). ICC/IF . PubMed: 20064371
  • Beerli RR  et al. Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J 6:224 (2009). Flow Cyt . PubMed: 20025741
  • Wang R  et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80:168-77 (2008). PubMed: 18598723
  • Hutchinson EC  et al. Mutational analysis of cis-acting RNA signals in segment 7 of influenza A virus. J Virol 82:11869-79 (2008). ICC/IF . PubMed: 18815307
  • Amorim MJ  et al. Nuclear export of influenza A virus mRNAs requires ongoing RNA polymerase II activity. Traffic 8:1-11 (2007). WB . PubMed: 17132145